

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

Voluntary Announcement

First Cohort of Subjects dosed for a Phase 1 Clinical Trial of SK-08 Tablet

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group. Reference is made to the announcement of the Company dated 17 July 2024 (the “**Announcement**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that the Group is conducting a Phase 1 trial for evaluating the safety, tolerability and pharmacokinetic of SK-08 Tablet. The first cohort of subjects has been successfully dosed.

Chronic kidney disease (“**CKD**”) represents a significant global public health challenge, posing severe risks to human health. In the PRC, the number of affected individuals has exceeded 100 million, with the incidence rate showing a consistent upward trend year by year. Patients with CKD experience a progressive decline in renal function, which may ultimately progress to end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation. This imposes substantial physical, emotional, and financial burdens on patients and their families.

SK-08 Tablet is a Category 1 innovative drug with global intellectual property rights jointly developed by the Group and another pharmaceutical company. Its unique mechanism of action precisely targets soluble guanylate cyclase (sGC), which is independent of the presence of nitric oxide, and promotes the generation of cGMP, which in turn can help reduce proteinuria and safeguard the functions of the kidney through multiple biological effects such as vasodilation, increasing kidney blood supply, improving glomerular filtration rate, anti-inflammation and anti-fibrosis. Additionally, it regulates reabsorption in the kidney, enhances cardiac function and mitigates the risks of thrombosis.

In preclinical trials, SK-08 Tablet significantly reduced proteinuria, improved kidney functions and alleviated glomerulosclerosis, and was well tolerated with good safety profile. Currently, there is no other drug adopting similar mechanism approved for the treatment of CKD across the world. SK-08 Tablet is expected to fill this gap and will provide a new treatment option for patients with CKD.

The Group envisages to promote prioritization of kidney health, early screening and prevention, and actively explore innovative treatment solutions, and the successful dosing of the first cohort of subjects marks another significant milestone for the Group in the development of innovative therapeutics for kidney disease.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 13 March 2025

As at the date of this announcement, the Board comprises Mr. An Meng and Professor Zhu Quan as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai and Mr. Li Zhuoguang as independent non-executive Directors.